Fusion Antibodies (FAB)

Executive Summary

Fusion Antibodies (AIM: FAB) is a UK-based contract research organization (CRO) specializing in end-to-end antibody discovery and development, from antigen design to cell line development. Founded in 2001 and headquartered in Belfast, the company partners with biotech and pharmaceutical clients to advance pre-clinical biologics, emphasizing manufacturability and commercialization. As the antibody therapeutics market grows, Fusion Antibodies is well-positioned to benefit from increasing outsourced R&D demand, particularly in the UK and European biotech ecosystem. The company's proprietary platforms, including its OptiMAL® and CDR grafting technologies, offer differentiated services that improve the speed and success rate of antibody humanization and optimization. Given its long track record and expertise, Fusion Antibodies serves as a trusted partner for early-stage drug development, though its financial performance has historically been volatile, with revenues dependent on project wins and milestones. Looking ahead, Fusion Antibodies faces both opportunities and challenges. The company is capitalizing on the broader trend toward biologic drugs and the need for specialized CRO support. Recent strategic moves to expand service offerings and invest in business development could drive revenue growth and margin improvement. However, the CRO space is competitive, with larger players like Abcam and smaller specialist firms vying for market share. Fusion Antibodies' success hinges on maintaining robust client relationships, securing repeat business, and demonstrating technical differentiation. With a lean cost structure and focus on high-value services, the company has the potential to achieve profitability as it scales. Near-term visibility is limited by the project-based nature of its business, but a strong pipeline of opportunities and potential strategic partnerships could catalyze performance.

Upcoming Catalysts (preview)

• Q4 2026Major pharma collaboration or licensing deal40% success
• Q1 2027Achievement of quarterly profitability or significant revenue growth55% success
• Q2 2026Expansion of service capacity or new technology platform launch50% success